Page 31 - Assurance of Sterility for Sensitive Combination Products and Materials
P. 31

Sensitive combination products   19


                                                               (B)        (C)






                                                  ACS       rhBMP-2
                                                       WFI           LT-CAGE TM
                                                Infuse TM  Bone graft kit  fixation device
                                                  Combined by physician at point of use  (D)



                                             Reconstitute
                                                      Soak ACS with
               (A)                          rhBMP-2 in WFI  rhBMP2 solution  Roll ACS into  Place ACS into
                                                              cylinder form
                                                                       LT-Device
                 Fig.  2.7  (A)  The Medtronic Infuse™ Bone Graft/LT-CAGE™ Lumbar  Tapered
                 Fusion Device in its combined form; (B) the Infuse™ Bone Graft kit components;
                 (C) the LT-CAGE device; and (D) procedure for combination at the point of use.
                 (Copyright Medtronic. LT-CAGE Incorporates Technology by Gary K. Michelson).

                 with formaldehyde and sterilization using ethylene oxide [17]. This process
                 can be problematic, as endotoxin removal can be an issue with such mate-
                 rials and there have been indeed product recalls by Integra Lifesciences, the
                 manufacturers that perform the sterilization of the scaffolds for Medtronic,
                 due to potential contamination issues. The rhBMP-2 and excipients are
                 lyophilized together and then sterilized using a nanofiltration process. The
                 three components are then combined by the physician at the point of use
                 in a sterile field using aseptic technique before implantation in the patient
                 (Fig. 2.7D). In this way, the manufacturer has avoided trying to identify a
                 suitable terminal sterilization method that would not adversely affect any of
                 the components if they were combined together and provided in a finished
                 form for off-the-shelf usage.




              2.2.4  Electronics, bioabsorbables, and other novel materials
              and the future of combination product development
              An article published by Robert Langer almost a decade ago was predictive
              of the ascendance of the combination product and described the conver-
              gence of two or more distinct scientific disciplines as the basis of a new
              device, process, or product (Fig. 2.8) [18]. The overlapping of advancements
              in the Biotechnology, Information Technology, and Nanotechnology arena
              provides opportunity to develop complex novel systems   encompassing
              wide-ranging functions such as microelectrical mechanical systems for
              sensing drug delivery, high-throughput biology and microarray technology,
   26   27   28   29   30   31   32   33   34   35   36